Loading
Cardiac Arrhythmia / Mobile Cardiac Telemetry / Cancer · Interventional Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a planned pilot study evaluating wearable cardiac monitors (mobile cardiac telemetry and investigational heart-sound monitor) to detect cardiotoxicity markers in adults with breast cancer, hematologic malignancy, or multiple myeloma during cancer treatment. No results are posted; the study has not yet begun recruitment and is designed to assess feasibility and validity of the monitoring approach.
Interventional, Single Group, Open label, Diagnostic purpose. Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma; age from 18 Years. Intervention: Mobile Cardiac Telemetry and Wearable Cardiac Monitor With…. n = 72. 1 site: United States.
This is a registry record for a planned pilot study evaluating wearable cardiac monitors (mobile cardiac telemetry and investigational heart-sound monitor) to detect cardiotoxicity markers in adults with breast cancer, hematologic malignancy, or multiple myeloma during cancer treatment. No results are posted; the study has not yet begun recruitment and is designed to assess feasibility and validity of the monitoring approach.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This pilot study will inform the feasibility and utility of wearable cardiac telemetry for early detection of treatment-related cardiac arrhythmias. Results, when available, may guide design of larger trials and inform clinical monitoring strategies in cancer cardio-oncology.
Pilot feasibility and validity study with no posted results; designed to evaluate monitoring devices and detection of arrhythmia markers in cancer patients, not yet recruiting.
As stated by the source record.
Quoted from the source exactly as published.
This pilot study will inform the feasibility and utility of wearable cardiac telemetry for early detection of treatment-related cardiac arrhythmias. Results, when available, may guide design of larger trials and inform clinical monitoring strategies in cancer cardio-oncology.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07776964). This is a study registration, not published results. Lead sponsor: University of Minnesota. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 72 participants (ESTIMATED). Conditions: Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma. Interventions: DEVICE: Mobile Cardiac Telemetry; DEVICE: Wearable Cardiac Monitor. Primary outcome measures: Incident Atrial or Ventricular Arrhythmia , Up to 12 months. Brief summary: This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment. Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers. Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.